<DOC>
	<DOCNO>NCT02783885</DOCNO>
	<brief_summary>The efficacy safety different medication vary one individual another one ethnic group another . Therefore , strong interest study pharmacogenomic pharmacoepidemiology evolve recently . There multiple example oncology drug effective certain ethnic population compare . For example , irinotecan combine cisplatin effective drug management small cell lung cancer Japanese patient identical study do US reveal major benefit combination American population</brief_summary>
	<brief_title>Clinical Utilization Newly Approved Oncology Medications</brief_title>
	<detailed_description>Another example benefit drawn tyrosine kinase inhibitor ( Erlotinib Gefitinib ) Asian patient . Immunotherapy new class cancer treatment work harness innate power immune system fight cancer . Because immune system 's unique property , therapy may hold great potential current treatment approach fight cancer powerfully , offer longer-term protection disease , come few side effect , benefit patient cancer type Immunotherapy include treatment work different way . Some boost body 's immune system general way . Others help train immune system attack cancer cell specifically . Immunotherapy become important part treat type cancer . Newer type immune treatment study , 'll impact treat cancer future . Recently , multiple immunotherapy treatment approve couple EGFR resistant medication . Many new oncology drug use Middle Eastern country include Saudi Arabia different indication without study Middle Eastern population . These medication ' efficacy safety profile may differ patient study drug development approval due difference population 's characteristic . The goal study observe , summarize report pattern use drug describe efficacy safety profile early phase use . The investigator aim build exist experience knowledge utilization classic methodology approach large scale effective way paint picture performance certain therapy real life world . The use prospective design help evaluate efficacy safety therapy already use practice , generate new hypothesis , and/or determine outcome certain disease .</detailed_description>
	<criteria>All patient cancer hematological malignancy receive new oncology medication ( defined medication first five year introduction ME market Patient accept participate study sign consent form</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>